Abstracts tagged "immunology"

Abstract Number: 2521 • ACR Convergence 2024
Clinicopathologic Associations Between Macrophage Location and Functional Profile in Giant Cell Arteritis
Michael Putman¹, Nader Khalidi², Carol Langford³, Curry Koening⁴, Christian Pagnoux⁵, David Cuthbertson⁶, Carol McAlear⁷ and Peter Merkel⁷, and the Vasculitis Clinical Research Consortium (VCRC), ¹The Medical College of Wisconsin, Milwaukee, WI, ²McMaster University, Hamilton, ON, Canada, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Texas Dell Medical School, Austin, TX, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶University of South Florida, Tampa, FL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Macrophages play a central role in the pathogenesis of giant cell arteritis (GCA), but few studies have correlated macrophage phenotype or topography from temporal…
Abstract Number: 0248 • ACR Convergence 2024
Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study
Nadia Aikawa¹, Ana Cristina Medeiros-Ribeiro², Sandra Pasoto³, Leonard Kupa³, Luciana Seguro⁴, ANA PAULA ASSAD³, Eduardo Borba³, Carla Goncalves Schahin Saad⁴, Emily Figueiredo Neves Yuki³, Danieli Andrade⁵, Andrea Shimabuco⁴, Karina Bonfiglioli³, Diogo Domiciano³, Julio Moraes³, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Henrique Giardini³, Joao de Oliveira³, Isabele Antonelli³, Renata Pinheiro³, Thais Bonini³, Marta Lopes⁶, Clovis Silva⁷ and Eloisa Bonfa³, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Infectious Disease Department, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at high risk of herpes zoster (HZ) due to their condition and treatment. The new recombinant vaccine…
Abstract Number: 1009 • ACR Convergence 2024
Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept
Kevin Winthrop¹, Jeremy Hawkins², Adriana Weinberg³, Sarah Siegel², Jessica Baxter³, Krystle Garth³, Joseph Huffstutter⁴, James Loveless⁵, Suzanne gharib⁶, Shanmugapriya (Priya) Reddy⁷, Jayashree Sinha⁸, Elvia Moreta⁹, David Ridley¹⁰, Ilhem Messaoudi¹¹ and Jeffrey Curtis¹², ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³University of Colorado, Aurora, CO, ⁴Arthritis Associates PLLC, Signal Mountain, TN, ⁵St Luke's Health System, Boise, ID, ⁶Charleston Area Medical Center, Charleston, MD, ⁷Southwest Florida Rheumatology, Riverview, FL, ⁸self employed, Clovis, NM, ⁹St. Paul Rheumatology, Eagan, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹University of Kentucky, Lexington, ¹²University of Alabama at Birmingham, Hoover, AL
Background/Purpose: The adjuvanted recombinant glycoprotein E (gE) herpes zoster vaccine (RZV) received expanded approval for use in 2021 for adults receiving immunosuppression. Despite approval, little…
Abstract Number: 1795 • ACR Convergence 2024
Immune Complexes-Mediated Activation of Neutrophils in Systemic Lupus Erythematosus Is Dependent on RNA Recognition by TLR8
Ting Wang¹, Runa Kuley², Payton Hermanson², Gundula Min-oo³, Natasha Crellin⁴, Ching Shang³ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³Gilead Sciences, Foster City, CA, ⁴Gilead, Foster City, CA
Background/Purpose: Neutrophil activation has been implicated to contribute to the systemic lupus erythematosus (SLE) pathogenesis. However, factors and mechanisms promoting neutrophil activation in SLE have…
Abstract Number: 1988 • ACR Convergence 2024
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Marta Cossu¹, Carolina Bobadilla Mendez², Amanda Jackson³, Eugene Myshkin⁴, Grace Liu⁵, Edwin Lam⁶, Ulf H. Beier², Kathleen Weisel², Brittney Scott², Jocelyn H. Leu⁶, Sheng Gao² and Dessislava Dimitrova², ¹Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, ³Janssen Research & Development, LLC, La Jolla, CA, ⁴Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson company, Raritan, NJ, ⁶Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA
Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…
Abstract Number: 2531 • ACR Convergence 2024
CRISPR Deletion Screen in Fibroblasts Identifies Novel Regulators of Inflammation
Alisa Mueller¹, Suppawat Kongthong², Angela Zou³, Gerald Watts⁴, Cassandra Murphy², Hung Nguyen², Jacqueline Perrigoue⁵, Mathew Chamberlain⁵, Kevin Wei⁶, Soumya Raychaudhuri² and Michael Brenner⁷, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Brookline, MA, ⁵Johnson & Johnson, Spring House, PA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts adopt an inflammatory phenotype that catalyzes pathogenic synovial hyperplasia and ultimately bone and cartilage destruction. However, identifying therapeutic…
Abstract Number: 0305 • ACR Convergence 2024
Inflammatory T Cell Expansion in Yao Syndrome
Danielle Xie¹, Rimanpreet Kaur², Richard Kew², Qingping Yao³ and Charles Vorkas², ¹Stony Brook University, East Setauket, ²Stony Brook University, Stony Brook, ³Stony Brook University, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, #OMIM 617321), formerly known as nucleotide-binding oligomerization protein containing 2 (NOD2)-associated autoinflammatory disease, is associated with specific NOD2 mutations and affects…
Abstract Number: 1171 • ACR Convergence 2024
Differences in Microbiome Profiles Based on Pain Severity and Inflammatory Biomarkers in Acute Low Back Pain
Rebecca Fillipo¹, Michael Brown², Jason Arnold², Colleen Burke³, Stephanie Danyluk², Kelley Seebeck² and Adam Goode², ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University School of Medicine, Chapel Hill, NC
Background/Purpose: Low Back Pain (LBP) is highly prevalent, with up to 25% of individuals experiencing LBP each year, with as many as 32% transitioning to…
Abstract Number: 1797 • ACR Convergence 2024
Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis
Carol Nassar¹, Rene Quevedo², M. Teresa Ciudad², Zoha Faheem³, Kieran Manion⁴, Carolina Munoz-Grajales⁵, Michael Kim⁶, Dafna Gladman⁷, Murray Urowitz⁸, Zahi Touma¹, Tracy McGaha⁹ and Joan Wither⁶, ¹University of Toronto, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵UHN/TWH, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Self employed, Toronto, ON, Canada, ⁹University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with severe morbidity and mortality. Around 70% of SLE patients follow a relapsing-remitting pattern…
Abstract Number: 1992 • ACR Convergence 2024
Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment
Austen herron¹, Miao Ting Lai², Naomi Schlesinger³, Sauer brian⁴, Jorge Rojas⁵, shardool Patel³, Madeline O’Sullivan³, grant Cannon⁶ and Tawnie Braaten³, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, salt lake city, ³University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Seattle VA, Mexico, Mexico, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Immune checkpoint inhibitors (ICIs) produce immune-related adverse events in patients with rheumatic diseases that can often present as a flare of the underlying condition.…
Abstract Number: 2538 • ACR Convergence 2024
HLA-DRB1 Rheumatoid Arthritis (RA) Risk Alleles Preferentially Select TRBJ2-3-containing CD4 T Cells in RA Patients
Amit Lakhanpal¹, Kazuyoshi Ishigaki², Anvita Singaraju¹, Alejandro Kochen³, Miriam Fein¹, Soumya Raychaudhuri⁴ and Laura Donlin¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan; Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q);; Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Bunkyo-ku, Tokyo, Japan, ³Yale School of Medicine, New Haven, CT, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The largest genetic risk factor for RA localizes to the MHC Class II HLA-DRB1 gene, which encodes the machinery for antigen presentation to CD4…
Abstract Number: 0324 • ACR Convergence 2024
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Daniel Nunez¹, Jenell Volkov¹, Jason Stadanlick¹, Zachary Vorndran¹, Alexandra Ellis¹, Mallorie Werner¹, Justin Cicarelli¹, Jazmean Williams¹, Fatemeh Nezhad¹, Thomas Furmanak², Quynh Lam¹, Rebecca Estremera¹, Yvonne White¹, Jonathan Hogan¹, Claire Miller¹, Tahseen Mozaffar³, Saira Sheikh⁴, David Chang¹ and Samik Basu¹, ¹Cabaletta Bio, Philadelphia, PA, ²Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, ³The University of California, Irvine, Orange, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
Abstract Number: 1381 • ACR Convergence 2024
Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis
Cécile Bergua¹, Marine Besnard¹, Ghenima Ahmil², Laure-Helene Ouisse², Nadège Vimond¹, Apolline Salama², Bérangère Evrard², Elise Brisebard³, Alexis Collette¹, Fréderic Blanchard⁴, Thibault Larcher³, Ronald Van Brempt¹, Benoit Le Goff⁵, Ignacio Anegon² and Carole Guillonneau¹, ¹AbolerIS Pharma, Nantes, France, Nantes, France, ²Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CNRS, Nantes, France, Nantes, France, ³APEX-UMR703 PAnTher INRA/ONIRIS, France, Nantes, France, ⁴INSERM UMR1229, Nantes, France, Nantes, France, ⁵CHU Nantes, France, Nantes, France
Background/Purpose: CD45RC is an isoform of CD45, a transmembrane tyrosine phosphatase, essential regulator of T and B cells antigen receptor signaling, expressed by most blood…
Abstract Number: 1824 • ACR Convergence 2024
Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial
Juliette Ferrant¹, Alain Lescoat², Valérie Lecureur³, Marie Lelong³, John Varga⁴, Robert Lafyatis⁵, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹CHU Rennes, Rennes, France, ²CHU Rennes - University Rennes 1, Rennes, France, ³Rennes University, Rennes, France, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Macrophages play a major role in dcSSc-related skin fibrosis, with a mixed M1-M2 activation profile relying on the activation of JAK/STAT. Tofacitinib, a pan-JAK…
Abstract Number: 1993 • ACR Convergence 2024
Identification of Elevated Soluble Factors in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Their Association with Severity and Persistence
Elise Gray-Gaillard¹, Clifton Bingham¹, Ami Shah² and Laura Cappelli³, ¹Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) are a type of cancer immunotherapy being implemented as the standard of care for an increasing number of malignancies. Due…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].